MaxCyte Q3 net loss narrows 62% to $4.76 million; revenue rises 49% to $10.15 million
MXCT•MaxCyte’s third-quarter 2026 net loss narrowed 62% year over year to $4.76 million, while revenue rose 49% to $10.15 million. The company raised full-year revenue guidance to at least $34.5 million, excluding its proposed Akron Bio acquisition.
1. Quarterly results
MaxCyte’s third-quarter 2026 net loss narrowed 62% year over year to $4.76 million. Revenue climbed 49% to $10.15 million, while core revenue rose 27% to $8.16 million.
2. Updated guidance
MaxCyte raised its full-year 2026 revenue guidance to at least $34.5 million, excluding the proposed acquisition of Akron Bio. The acquisition would expand its offering across cell therapy manufacturing.
